- Telehealth visits
Cheryl Peretz, MD
Pediatric Hematology-Oncology- Telehealth visits
Cheryl Peretz, MD
Pediatric Hematology-Oncology- Telehealth visits
On this page
About me
Dr. Cheryl Peretz is a pediatric hematologist-oncologist who provides care for many types of cancer in children. She specializes in difficult-to-treat blood cancers.
In research, Peretz focuses on myeloid leukemia, primarily acute myeloid leukemia (AML). Her studies also investigate mixed phenotype acute leukemia (a rare form of leukemia that combines AML and acute lymphoblastic leukemia) and other leukemias in which there is a genetic predisposition. She is particularly interested in how genetic alterations make some leukemias resist standard treatments.
After earning a bachelor's degree in the biological basis of behavior from the University of Pennsylvania, Peretz earned her medical degree from the University of Connecticut School of Medicine. She completed a residency in pediatrics at UCSF and a fellowship in pediatric hematology and oncology at UCSF Benioff Children's Hospital Oakland.
Education & training
Board certification
- Pediatric Hematology-Oncology, American Board of Pediatrics
- Pediatrics, American Board of Pediatrics
Fellowship
- Pediatric Hematology-Oncology, UCSF Benioff Children's Hospital - Oakland GME
Residency
- Pediatrics, UCSF School of Medicine -GME
Internship
- Pediatrics, UCSF School of Medicine -GME
Degree
- MD, University of Connecticut School of Medicine
Academic Title
- Adjunct Professor
My expertise
Specialties
- Pediatric Hematology-Oncology
Locations
My research
Publications
Please check with your health insurance plan regarding coverage for this type of care. Not all providers at UCSF Health are covered by every insurance plan.
For informational purposes only, a link to the federal Centers for Medicare and Medicaid Services (CMS) Open Payments web page is provided here.
The federal Physician Payments Sunshine Act requires that detailed information about payment and other payments of value worth over ten dollars ($10) from manufacturers of drugs, medical devices, and biologics to physicians and teaching hospitals be made available to the public.